Form 4: Plus Therapeutics Director Greg Petersen Reports Securities Transactions

Director Greg Petersen of Plus Therapeutics reports the acquisition and disposal of common stock and warrants.

Summary

• On May 8, 2024, Greg Petersen, a director of Plus Therapeutics, engaged in transactions involving the company's securities.
• Petersen acquired 12,255 shares of common stock at a price of $2.04 per share.
• Following this transaction, Petersen directly owns 36,421 shares of common stock.
• Petersen also acquired 24,510 warrants with an exercise price of $1.79.
• Half of the warrants (12,255) are Series A warrants expiring on May 8, 2029, and the other half (12,255) are Series B warrants expiring one year after the effectiveness of a registration statement covering the resale of the underlying common stock.
• Petersen disposed of 24,510 warrants.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates

Keywords

Form 4, Beneficial Ownership, Securities Transactions, Warrants, Common Stock, Plus Therapeutics, Director, PSTV, Greg Petersen